Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, regulatory-update
Related Tickers: APVO
TL;DR
APVO filed an 8-K, standard update, no major news yet.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on December 4, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text, but it serves as a standard regulatory update.
Why It Matters
This filing indicates Aptevo Therapeutics is making a regulatory submission to the SEC, which is a standard procedure for public companies to disclose material information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- December 04, 2024 (date) — Date of earliest event reported
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the purpose of this 8-K filing by Aptevo Therapeutics Inc.?
The 8-K filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 04, 2024.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The address of the Principal Executive Offices is 2401 4th Avenue Suite 1050, Seattle, Washington 98121.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number for Aptevo Therapeutics Inc. is 001-37746.
Does this filing contain specific financial details or new material events?
Based on the provided text, this filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' and does not detail specific new material events or financial figures.
Filing Stats: 463 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-12-04 08:45:09
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20241204.htm (8-K) — 40KB
- apvo-ex99_1.htm (EX-99.1) — 23KB
- img237228349_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-133091.txt ( ) — 191KB
- apvo-20241204.xsd (EX-101.SCH) — 25KB
- apvo-20241204_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 4, 2024, Aptevo Therapeutics Inc. ("Aptevo" or the "Company") issued a press release providing additional details about the Company's preclinical molecule, APVO442, a multispecific antibody differentiated to enhance prostate cancer treatment with precision tumor targeting and reduced risk of side effect. APVO442 is the first molecule developed using Aptevo's cutting-edge ADAPTIR-FLEX platform, which is driving innovation in antibody engineering for complex disease management. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: December 4, 2024 By: /s/ Marvin L. White President and Chief Executive Officer